Subsidiary of Zhejiang Jiuzhou Pharmaceutical (603456.SH) obtains drug registration certificate.
Jiuzhou Pharmaceutical (603456.SH) announced recently that its subsidiaries Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd. and Zhejiang Jiuzhou Biopharmaceutical Co., Ltd. have received the "Drug Registration Certificate" for Fumarate Vynosololion tablets and Sitagliptin Metformin Extended-release tablets approved and issued by the National Drug Administration.
Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its subsidiaries Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd. and Zhejiang Jiuzhou Biopharmaceutical Co., Ltd. have recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Fumarate Fovinara Effervescent Tablets and Sitagliptin Metformin Extended-release Tablets.
Fumarate Fovinara Effervescent Tablets are used for the treatment of reflux esophagitis and in combination with appropriate antibiotics to eradicate Helicobacter pylori. Sitagliptin Metformin Extended-release Tablets are used in the treatment of adult type 2 diabetes patients who are already receiving Sitagliptin and Metformin Extended-release Tablets in combination.
Related Articles
On June 16, SBP GROUP (01177) spent 49.2319 million Hong Kong dollars to repurchase 10.512 million shares.
China Mobile Limited (00941): Chen Yangfan appointed as Executive Director and Chief Executive Officer.
Trustee purchases a total of 1 million shares in accordance with the restricted stock award plan.
On June 16, SBP GROUP (01177) spent 49.2319 million Hong Kong dollars to repurchase 10.512 million shares.
China Mobile Limited (00941): Chen Yangfan appointed as Executive Director and Chief Executive Officer.
Trustee purchases a total of 1 million shares in accordance with the restricted stock award plan.
RECOMMEND
